HTTP 200 OK
Allow: GET, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept
{
"count": 127182,
"next": "https://api-test.medunigraz.at/v1/research/search/publication/?format=api&limit=20&offset=124440",
"previous": "https://api-test.medunigraz.at/v1/research/search/publication/?format=api&limit=20&offset=124400",
"results": [
{
"text": "\n182515\nFunctional Assessment and Patient-Related Outcomes after Gluteus Maximus Flap Transfer in Patients with Severe Hip Abductor Deficiency.\n\nRuckenstuhl, P\n\nWassilew, GI\n\nMüller, M\n\nHipfl, C\n\nPumberger, M\n\nPerka, C\n\nHardt, S\n\nBeiträge in Fachzeitschriften\nISI:000549332600001\n32545269.0\n10.3390/jcm9061823\nPMC7356154\n(1) Background: Degeneration of the hip abductor mechanism, a well-known cause of functional limitation, is difficult to treat and is associated with a reduced health-related quality of life (HRQOL). The gluteus maximus muscle flap is a treatment option to support a severely degenerative modified gluteus medius muscle. Although several reports exist on the clinical outcome, there remains a gap in the literature regarding HRQOL in conjunction with functional results. (2) Methods: The present study consists of 18 patients with a mean age of 64 (53‒79) years, operatively treated with a gluteus maximus flap due to chronic gluteal deficiency. Fifteen (83%) of these patients presented a history of total hip arthroplasty or revision arthroplasty. Pre and postoperative pain, Trendelenburg sign, internal rotation lag sign, trochanteric pain syndrome, the Harris Hip Score (HHS), and abduction strength after Janda (0‒5) were evaluated. Postoperative patient satisfaction and health-related quality of life, according to the Short Form 36 (SF-36), were used as patient-reported outcome measurements (PROMs). Postoperative MRI scans were performed in 13 cases (72%). (3) Results: Local pain decreased from NRS 6.1 (0-10) to 4.9 (0-8) and 44% presented with a negative Trendelenburg sign postoperatively. The overall HHS results (p = 0.42) and muscular abduction strength (p = 0.32) increased without significance. The postoperative HRQOL reached 46.8 points (31.3-62.6) for the mental component score and 37.1 points (26.9-54.7) for the physical component score. The physical component results presented a high level of positive correlation with HHS scores postoperatively (R = 0.88, p < 0.001). Moreover, 72% reported that they would undergo the operative treatment again. The MRI overall showed no significant further loss of muscle volume and no further degeneration of muscular tissue. (4) Conclusions: Along with fair functional results, the patients treated with a gluteus maximus flap transfer presented satisfying long-term PROMs. Given this condition, the gluteus maximus muscle flap transfer is a viable option for selected patients with chronic gluteal deficiency.\n\nRuckenstuhl, Paul\n\n\n"
},
{
"text": "\n187633\nCuration and Expansion of Human Phenotype Ontology for Defined Groups of Inborn Errors of Immunity.\n\nHaimel, M\n\nPazmandi, J\n\nHeredia, RJ\n\nDmytrus, J\n\nBal, SK\n\nZoghi, S\n\nvan Daele, P\n\nBriggs, TA\n\nWouters, C\n\nBader-Meunier, B\n\nAeschlimann, FA\n\nCaorsi, R\n\nEleftheriou, D\n\nHoppenreijs, E\n\nSalzer, E\n\nBakhtiar, S\n\nDerfalvi, B\n\nSaettini, F\n\nKusters, MAA\n\nElfeky, R\n\nTrück, J\n\nRivière, JG\n\nvan der Burg, M\n\nGattorno, M\n\nSeidel, MG\n\nBurns, S\n\nWarnatz, K\n\nHauck, F\n\nBrogan, P\n\nGilmour, KC\n\nSchuetz, C\n\nSimon, A\n\nBock, C\n\nHambleton, S\n\nde Vries, E\n\nRobinson, P\n\nvan Gijn, M\n\nBoztug, K\n\nBeiträge in Fachzeitschriften\nNone\n33991581.0\n10.1016/j.jaci.2021.04.033\nNone\nAccurate, detailed and standardized phenotypic descriptions are essential to support diagnostic interpretation of genetic variants and to discover new diseases. The Human Phenotype Ontology (HPO), extensively used in rare disease research, provides a rich collection of vocabulary with standardized phenotypic descriptions in a hierarchical structure. However, to date the use of HPO has not yet been widely implemented in the field of inborn errors of immunity (IEIs), mainly due to a lack of comprehensive IEI-related terms.\n We sought to systematically review available terms in HPO for the depiction of IEIs, to expand HPO yielding more comprehensive sets of terms, and to reannotate IEIs with HPO terms to provide accurate, standardized phenotypic descriptions.\n We initiated a collaboration involving expert clinicians, geneticists, researchers working on IEIs and bioinformaticians. Multiple branches of the HPO tree were restructured and extended based on expert review. Our ontology-guided machine learning coupled with a two-tier expert review was applied to reannotate defined subgroups of IEIs.\n We revised and expanded four main branches of the HPO tree. Here, we reannotated 73 diseases from four IUIS-defined IEI disease subgroups with HPO terms. We achieved a 4.7-fold increase in number of phenotypic terms per disease. Given the new HPO annotations, we demonstrated improved ability to computationally match selected IEI cases to their known diagnosis, and improved phenotype-driven disease classification.\n Our targeted expansion and reannotation presents enhanced precision of disease annotation, will enable superior HPO-based IEI characterization and hence benefit both IEI diagnostic and research activities.\n Copyright © 2021. Published by Elsevier Inc.\n\nSeidel, Markus\n\n\n"
},
{
"text": "\n1902\nPartial liquid ventilation combined with inhaled nitric oxide in acute respiratory failure with pulmonary hypertension in piglets.\n\nZobel, G\n\nUrlesberger, B\n\nDacar, D\n\nRödl, S\n\nReiterer, F\n\nFriehs, I\n\nBeiträge in Fachzeitschriften\nISI:A1997WF27300003\n9029634.0\n10.1203/00006450-199702000-00003\nNone\nThis study was a prospective, randomized, controlled design to evaluate gas exchange, lung mechanics, and pulmonary hemodynamics during partial liquid ventilation (PLV) combined with inhaled nitric oxide (NO) in acute respiratory failure (ARF) with pulmonary hypertension (PH). ARF with PH was induced in 12 piglets weighing 9.7-13.7 kg by repeated lung lavages and the continuous infusion of the stable endoperoxane analog of thromboxane. Thereafter the animals were randomly assigned either for PLV or conventional mechanical ventilation (CMV) at a fractional concentration of inspired O2 (Fio2) of 1.0. Perfluorocarbon (PFC) liquid (30 mL kg-1) was instilled into the endotracheal tube over 5 min followed by 5 mL kg-1h-1. All animals were treated with different concentrations of NO (1-10-20 ppm) inhaled in random order. Continuous monitoring included ECG, right atrial (Pra), mean pulmonary artery (Ppa), pulmonary capillary (Ppc'), and mean arterial (Pa) pressures, arteria oxygen saturation, and mixed venous oxygen saturation measurements. During PLV Pao2/Fio2 increased significantly from 8.2 +/- 0.4 kPa to 34.8 +/- 5.1 kPa (p < 0.01), whereas Pao2/FiO2 remained constant at 9.5 +/- 0.4 kPa during CMV. The infusion of the endoperoxane analog resulted in a sudden decrease of Pao2/Fio2 from 34.8 +/- 5.1 kPa to 14.1 +/- 0.4 kPa (p < 0.01) in the PLV group and from 9.5 +/- 0.4 kPa to 6.9 +/- 0.2 kPa (p < 0.05) in the control group. Inhaled NO significantly improved oxygenation in both groups (Pao2/Fio2: 45.7 +/- 5.3 kPa during PLV and 25.9 +/- 4.7 kPa during CMV). During inhalation of NO mean Ppa decreased significantly from 7.8 +/- 0.26 kPa to 4.2 +/- 0.26 kPa (p < 0.01) in the PLV group and from 7.4 +/- 0.26 kPa to 5.1 +/- 0.13 kPa (p < 0.01) in the control group. As documented in the literature PLV significantly improves oxygenation and lung mechanics in severe ARF. In addition, when ARF is associated with severe PH, the combined treatment of PLV and inhaled NO improves pulmonary hemodynamics resulting in better oxygenation.\n\nReiterer, Friedrich\n\nRoedl, Siegfried\n\nUrlesberger, Berndt\n\n\n"
},
{
"text": "\n2355\nSigma S, a measure of reactive sulfur groups of immunoglobulin G, is a sensitive tumor marker discriminating different stages of breast cancer.\n\nSmola, MG\n\nEstelberger, W\n\nReiter, M\n\nSchauenstein, K\n\nSchauenstein, E\n\nBeiträge in Fachzeitschriften\nISI:A1991GD02500019\n1913474.0\n10.1002/1097-0142(19910901)68:5<1026::AID-CNCR2820680520>3.0.CO;2-H\nNone\nSigma S is a measure of the disulfide bonds and free thiol groups of serum immunoglobulin (Ig) G, as determined by the reaction with dithionitrobenzoate. Significant decreases of sigma S previously were detected in malignant compared with benign diseases of various organs. This study shows the application of sigma S for the diagnosis of breast cancer. The following results were obtained. First, 132 patients with benign breast diseases showed a sigma S of 1.48 +/- 0.29 (standard deviation) per mole IgG; this was not different from 1.51 +/- 0.36 found in 182 controls. In contrast, IgG from 198 patients with primary breast carcinoma of all four stages (tumor-node-metastasis system) gave a sigma S of 1.22 +/- 0.29, a significant (P less than 0.0001) decrease of sigma S from benign to malignant breast disease. Second, sigma S values of single Stages I, II, III, and IV, were 1.27 (n = 59), 1.23 (n = 83), 1.19 (n = 35), and 1.10 (n = 21), respectively, each significantly different from sigma S in benign disease and showing a decreasing trend with increasing tumor progress. Differences were significant between Stages I and IV (P less than 0.025) and II and IV (P less than 0.05). Third, 63% of Stage I breast carcinoma patients had sigma S values below a critical threshold of 1.38. This serum positivity rose to 90% in Stage IV. These values exceeded those reported with other tumor markers. The overall power of sigma S to distinguish between benign and malignant breast disease had a specificity of 61% and a sensitivity of 78%. Early stages (I and II) of breast cancer could be distinguished from benign diseases with 64% specificity and 69% sensitivity. Advanced Stage IV could be discriminated from early Stages I and II with 55% specificity and 71% sensitivity. Thus, the analysis of sigma S may significantly contribute to the surveillance of patients with breast cancer.\n\n\n"
},
{
"text": "\n5029\nRelationships between bioelectric impedance and subcutaneous adipose tissue thickness measured by LIPOMETER and skinfold calipers in children.\n\nJurimae, T\n\nSudi, K\n\nPayerl, D\n\nLeppik, A\n\nJurimae, J\n\nMöller, R\n\nTafeit, E\n\nBeiträge in Fachzeitschriften\nISI:000185457700026\n14504951.0\n10.1007/s00421-003-0878-3\nNone\nThe aim of this study was to compare the relationships between bioelectrical impedance and thicknesses of adipose tissue measured by traditional skinfold caliper (double thickness) or a LIPOMETER device (single non-compressed thickness) in 9- to 12-year-old boys ( n=52) and girls ( n=44). In total, nine skinfolds (triceps, subscapular, biceps, iliac crest, supraspinale, abdominal, front thigh, medial calf, mid-axilla) were measured. Measurement for the thickness of subcutaneous adipose tissue layers (SAT-layers) by LIPOMETER were performed at 15 body sites (neck, triceps, biceps, upper back, front chest, lateral chest, upper abdomen, lower abdomen, lower back, hip, front thigh, lateral thigh, rear thigh, inner thigh, calf). Body bioelectrical impedance was measured with a multiple-frequency impedance device Multiscan-5000 (Bodystat, UK). Impedance at 50 kHz highly correlated with body mass ( r=-0.47 in boys, r=-0.46 in girls, r=-0.47 in total group). The relationship with body height was significant only in girls ( r=-0.42). Skinfold thicknesses measured by caliper did not correlate significantly with body impedance at 50 kHz. SAT-layers measured by LIPOMETER at triceps, front thigh, lateral thigh and rear thigh sites in boys and at the lateral thigh site in girls correlated significantly with body impedance measured at 50 kHz. Stepwise multiple regression analysis indicated that the iliac crest and front thigh skinfold thicknesses measured by caliper characterized only 5.7-12.0% of the impedance at 50 kHz in the total group ( n=96). From the measured 15 SAT-layers, the most significant was the lateral thigh layer which characterized 20.0%, 11.9% and 13.6% of the impedance at 50 kHz in boys, girls and the total group, respectively. It was concluded that the influence of subcutaneous adipose tissue on body impedance is relatively low in children. However, SAT-layers have a slightly higher influence on body impedance than skinfold thicknesses measured by caliper. The sum of skinfolds or SAT-layers did not correlate significantly with body impedance in any group.\n\nPayerl, Doris\n\nTafeit, Erwin\n\n\n"
},
{
"text": "\n5095\nStimulation of the nitric oxide-guanosine 3', 5'-cyclic monophosphate pathway by sildenafil: effect on rectal muscle tone, distensibility, and perception in health and in irritable bowel syndrome.\n\nFritz, E\n\nHammer, J\n\nSchmidt, B\n\nEherer, AJ\n\nHammer, HF\n\nBeiträge in Fachzeitschriften\nISI:000186037200025\n14572576.0\n10.1111/j.1572-0241.2003.07661.x\nNone\nOBJECTIVES: Nitric oxide, a neurotransmitter in the noncholinergic, nonadrenergic nervous system, is a mediator of relaxation of GI smooth muscle and of visceral nociception mainly studied in vitro. Sildenafil stimulates the nitric oxide guanosine 3', 5'-cyclic monophosphate (NO-cGMP) pathway through inhibition of phosphodiesterase 5. The aims of this study were to evaluate in vivo the effect of stimulation of the NO-cGMP pathway on rectal tone, distensibility, and perception in healthy individuals and in patients with irritable bowel syndrome (IBS).METHODS: In eight healthy subjects and four patients with IBS rectal tone, distensibility and perception thresholds were measured with an electronic barostat both before and 60 min after administration of sildenafil (50 mg p.o.). Perception was scored on a graded scale of 0-6. At the end of a distension series an anatomic questionnaire was filled out by the subjects.RESULTS: Sildenafil significantly reduced rectal tone in healthy subjects (intrabag volume predrug: 145.5 +/- 18.7 ml vs postdrug: 164.4 +/- 16.9 ml, p = 0.01) and IBS (111.3 +/- 25.2 ml vs 136.5 +/- 33.3 ml; p = 0.01) but did not alter rectal compliance (healthy subjects: 5.8 +/- 0.4 vs 6.3 +/- 0.6 ml/mm Hg, p > 0.05; IBS subjects: 6.1 +/- 0.6 vs 7.1 +/- 1.0 ml/mm Hg, p > 0.05). Intrabag pressure and rectal wall tension to reach perception thresholds for initial sensation, sensation of stool, and urgency were not altered by sildenafil. However, intrabag volumes to reach these thresholds were significantly increased by sildenafil both in healthy subjects and in patients with IBS. Viscerosomatic referral was unchanged.CONCLUSIONS: Stimulation of the NO-cGMP pathway decreases rectal tone but does not influence rectal distensibility. Relaxation of the rectum is accompanied by an increase in rectal volumes to reach perception thresholds in healthy subjects and in patients with IBS, but no direct effect on rectal perception can be demonstrated.\n\nEherer, Andreas\n\nHammer, Heinz\n\n\n"
},
{
"text": "\n71181\nInfluence of Forskolin on the force-frequency behavior in nonfailing and end-stage failing human myocardium\n\nPieske, B\n\nTrost, S\n\nSchutt, K\n\nMinami, K\n\nJust, H\n\nHasenfuss, G\n\nBeiträge in Fachzeitschriften\nISI:000076970700009\n9833133.0\nNone\nNone\nEnd-stage failing human myocardium is characterized by a negative force-frequency relationship (FFR), possibly as a result of reduced SR Ca2+ uptake capacity. We investigated the effects of the direct adenylate cyclase stimulator, forskolin, on force of contraction and FFR in isolated human myocardium from 7 nonfailing hearts (NF) and end-stage failing hearts (NYHA IV) due to either ischemic (ICM; n = 13) or dilated cardiomyopathy (DCM; n = 16). METHODS: Isolated left ventricular muscle strips, isometric contraction, electrical stimulation at a basal stimulation rate of 1 Hz (37 degrees C). Inotropic responses: Cumulative concentration-response curves for forskolin (0.01-10 microM) and for Ca2+ (2.5-15 mM). Force-frequency experiments: stepwise increase in stimulation rate from 0.5 to 3.0 Hz without and in the presence of 0.3, 1.0 or 3.0 microM forskolin. RESULTS: Forskolin concentration-dependently increased force of contraction to 386 +/- 28% (n = 5) in NF, to 256 +/- 48% (n = 7) in ICM, and to 212 +/- 13% (n = 14) in DCM. The effectiveness of forskolin was significantly reduced in failing myocardium. Ca2+ increased force of contraction to maximally 438 +/- 108% in NF, to 267 +/- 15% in ICM, and to 292 +/- 20% in DCM. Again, the effectiveness of Ca2+ was significantly reduced in failing myocardium. Forskolin activated contractile reserve to similar extents in all types of myocardium (90%, 95%, and 82%, respectively). Force of contraction continuously increased with increasing stimulation rates in nonfailing myocardium (positive FFR), but was blunted or inversed in ICM and DCM. Prestimulation with forskolin (0.3 microM) further enhanced frequency-potentiation in nonfailing, and normalized the slope and optimum stimulation frequency in ICM and DCM. However, at higher concentrations of forskolin, FFR was blunted or inversed in non-failing myocardium, and further impaired in failing myocardium. CONCLUSION: Low concentrations of forskolin with only marginal inotropic effects may partially normalize the inverse force-frequency relation in end-stage failing human myocardium. Reduced cAMP levels in conjunction with reduced expression of SR Ca2+ ATPase may be the underlying cause for altered excitation-contraction coupling in diseased human hearts.\n\n\n"
},
{
"text": "\n82631\nHigher immunoglobulin E antibody levels to recombinant Fel d 1 in cat-allergic children with asthma compared with rhinoconjunctivitis.\n\nGronlund, H\n\nAdedoyin, J\n\nReininger, R\n\nVarga, EM\n\nZach, M\n\nFredriksson, M\n\nKronqvist, M\n\nSzepfalusiz, Z\n\nSpitzauer, S\n\nGronneberg, R\n\nValenta, R\n\nHedlin, G\n\nvan Hage, M\n\nBeiträge in Fachzeitschriften\nISI:000257778300006\n18477016.0\n10.1111/j.1365-2222.2008.03003.x\nNone\nBACKGROUND: Current diagnosis of allergy and asthma to cat is confirmed using cat dander extract (CDE). We have previously engineered a recombinant major cat allergen, rFel d 1, with properties identical to the natural molecule. OBJECTIVE: The aim of the study was to evaluate IgE and IgG4 antibodies to rFel d 1 among sera from cat-allergic children and adults suffering from asthma and/or rhinoconjunctivitis (RC) in populations from Sweden and Austria. METHODS: Cat-allergic children and adults from Sweden (n=27 and 31, respectively) and Austria (n=41 and 41) with RC and/or asthma were selected. Sera were tested for IgE and IgG4 antibodies to CDE and rFel d 1 by CAP, and IgE to rFel d 1 by ELISA. Healthy subjects and non-cat-allergic patients (n=75) were included as controls. RESULTS: There was a high correlation between IgE responses to rFel d 1 and CDE among the 140 patients (r(s)=0.85, P<0.001); however, measured levels to rFel d 1 were on average 30% higher (P<0.0001). Ninety-eight percent of patients and none of the controls showed IgE to rFel d 1 and there was a threefold increased risk of asthma for half of the children with the highest IgE levels [odds ratio 3.23; 95% confidence interval (CI), 1.19-8.79] by ELISA. IgE responses to rFel d 1 among children with asthma were higher (median 19.4 kU/L) compared with children with RC (median 6.6 kU/L, P<0.05) and adults with asthma (median 3.0 kU/L, P<0.01). Furthermore, children with asthma displayed higher IgG4 levels than the asthmatic adults. CONCLUSION: A single recombinant molecule, rFel d 1, is at least as sensitive for in vitro diagnostics of cat allergy as the current extract-based test. Elevated IgE antibody levels to Fel d 1 are suggested to be a risk factor for asthma in cat-allergic children.\n\nVarga, Eva-Maria\n\n\n"
},
{
"text": "\n82917\nComparative transcriptomics of human multipotent stem cells during adipogenesis and osteoblastogenesis\n\nScheideler, M\n\nElabd, C\n\nZaragosi, LE\n\nChiellini, C\n\nHackl, H\n\nSanchez-Cabo, F\n\nYadav, S\n\nDuszka, K\n\nFriedl, G\n\nPapak, C\n\nProkesch, A\n\nWindhager, R\n\nAilhaud, G\n\nDani, C\n\nAmri, EZ\n\nTrajanoski, Z\n\nBeiträge in Fachzeitschriften\nISI:000258139800002\n18637193.0\n10.1186/1471-2164-9-340\nPMC2492879\nA reciprocal relationship between bone and fat development in osteoporosis is clinically well established. Some of the key molecular regulators involved in this tissue replacement process have been identified. The detailed mechanisms governing the differentiation of mesenchymal stem cells (MSC) - the key cells involved - are however only now beginning to emerge. In an attempt to address the regulation of the adipocyte/osteoblast balance at the level of gene transcription in a comprehensive and unbiased manner, we performed a large-scale gene expression profiling study using a unique cellular model, human multipotent adipose tissue-derived stem cells (hMADS).\n The analysis of 1606 genes that were found to be differentially expressed between adipogenesis and osteoblastogenesis revealed gene repression to be most prevalent prior to commitment in both lineages. Computational analyses suggested that this gene repression is mediated by miRNAs. The transcriptional activation of lineage-specific molecular processes in both cases occurred predominantly after commitment. Analyses of the gene expression data and promoter sequences produced a set of 65 genes that are candidates for genes involved in the process of adipocyte/osteoblast commitment. Four of these genes were studied in more detail: LXRalpha and phospholipid transfer protein (PLTP) for adipogenesis, the nuclear receptor COUP-TF1 and one uncharacterized gene, TMEM135 for osteoblastogenesis. PLTP was secreted during both early and late time points of hMADS adipocyte differentiation. LXRalpha, COUP-TF1, and the transmembrane protein TMEM135 were studied in primary cultures of differentiating bone marrow stromal cells from healthy donors and were found to be transcriptionally activated in the corresponding lineages.\n Our results reveal gene repression as a predominant early mechanism before final cell commitment. We were moreover able to identify 65 genes as candidates for genes controlling the adipocyte/osteoblast balance and to further evaluate four of these. Additional studies will explore the precise role of these candidate genes in regulating the adipogenesis/osteoblastogenesis switch.\n\nProkesch, Andreas\n\n\n"
},
{
"text": "\n106036\nA genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1.\n\nGenetic Analysis of Psoriasis Consortium &\n\nthe Wellcome Trust Case Control Consortium 2\n\nStrange, A\n\nCapon, F\n\nSpencer, CC\n\nKnight, J\n\nWeale, ME\n\nAllen, MH\n\nBarton, A\n\nBand, G\n\nBellenguez, C\n\nBergboer, JG\n\nBlackwell, JM\n\nBramon, E\n\nBumpstead, SJ\n\nCasas, JP\n\nCork, MJ\n\nCorvin, A\n\nDeloukas, P\n\nDilthey, A\n\nDuncanson, A\n\nEdkins, S\n\nEstivill, X\n\nFitzgerald, O\n\nFreeman, C\n\nGiardina, E\n\nGray, E\n\nHofer, A\n\nHüffmeier, U\n\nHunt, SE\n\nIrvine, AD\n\nJankowski, J\n\nKirby, B\n\nLangford, C\n\nLascorz, J\n\nLeman, J\n\nLeslie, S\n\nMallbris, L\n\nMarkus, HS\n\nMathew, CG\n\nMcLean, WH\n\nMcManus, R\n\nMössner, R\n\nMoutsianas, L\n\nNaluai, AT\n\nNestle, FO\n\nNovelli, G\n\nOnoufriadis, A\n\nPalmer, CN\n\nPerricone, C\n\nPirinen, M\n\nPlomin, R\n\nPotter, SC\n\nPujol, RM\n\nRautanen, A\n\nRiveira-Munoz, E\n\nRyan, AW\n\nSalmhofer, W\n\nSamuelsson, L\n\nSawcer, SJ\n\nSchalkwijk, J\n\nSmith, CH\n\nStåhle, M\n\nSu, Z\n\nTazi-Ahnini, R\n\nTraupe, H\n\nViswanathan, AC\n\nWarren, RB\n\nWeger, W\n\nWolk, K\n\nWood, N\n\nWorthington, J\n\nYoung, HS\n\nZeeuwen, PL\n\nHayday, A\n\nBurden, AD\n\nGriffiths, CE\n\nKere, J\n\nReis, A\n\nMcVean, G\n\nEvans, DM\n\nBrown, MA\n\nBarker, JN\n\nPeltonen, L\n\nDonnelly, P\n\nTrembath, RC\n\nBeiträge in Fachzeitschriften\nISI:000283540500016\n20953190.0\n10.1038/ng.694\nPMC3749730\nTo identify new susceptibility loci for psoriasis, we undertook a genome-wide association study of 594, 24 SNPs in 2, 22 individuals with psoriasis and 5, 67 controls. We identified associations at eight previously unreported genomic loci. Seven loci harbored genes with recognized immune functions (IL28RA, REL, IFIH1, ERAP1, TRAF3IP2, NFKBIA and TYK2). These associations were replicated in 9, 79 European samples (six loci with a combined P < 5 × 10⁻⁸ and two loci with a combined P < 5 × 10⁻⁷). We also report compelling evidence for an interaction between the HLA-C and ERAP1 loci (combined P = 6.95 × 10⁻⁶). ERAP1 plays an important role in MHC class I peptide processing. ERAP1 variants only influenced psoriasis susceptibility in individuals carrying the HLA-C risk allele. Our findings implicate pathways that integrate epidermal barrier dysfunction with innate and adaptive immune dysregulation in psoriasis pathogenesis.\n\nHofer, Angelika\n\nSalmhofer, Wolfgang\n\nWeger, Wolfgang\n\nWolf, Peter\n\n\n"
},
{
"text": "\n120862\nComputer-based symptom assessment is feasible in patients with advanced cancer: results from an international multicenter study, the EPCRC-CSA.\n\nHjermstad, MJ\n\nLie, HC\n\nCaraceni, A\n\nCurrow, DC\n\nFainsinger, RL\n\nGundersen, OE\n\nHaugen, DF\n\nHeitzer, E\n\nRadbruch, L\n\nStone, PC\n\nStrasser, F\n\nKaasa, S\n\nLoge, JH\n\nEuropean Palliative Care Research Collaborative (EPCRC)\n\nBeiträge in Fachzeitschriften\nISI:000311570400004\n22795905.0\n10.1016/j.jpainsymman.2011.10.025\nNone\nContext. Symptom assessment by computers is only effective if it provides valid results and is perceived as useful for clinical use by the end users: patients and health care providers.\nObjectives. To identify factors associated with discontinuation, time expenditure, and patient preferences of the computerized symptom assessment used in an international multicenter data collection project: the European Palliative Care Research Collaborative-Computerized Symptom Assessment.\nMethods. Cancer patients with incurable metastatic or locally advanced disease were recruited from 17 centers in eight countries, providing 1017 records for analyses. Observer-based registrations and patient-reported measures on pain, depression, and physical function were entered on touch screen laptop computers.\nResults. The entire assessment was completed by 94.9% (n = 965), with median age 63 years (range 18-91 years) and median Karnofsky Performance Status (KPS) score of 70 (range 20-100). Predictive factors for noncompletion were higher age, lower KPS, and more pain (P ANDlt;= 0.012). Time expenditure among completers increased with higher age, male gender, Norwegian nationality, number of comorbidities, and lower physical functioning (P ANDlt;= 0.007) but was inversely related to pain levels and tiredness (P ANDlt;= 0.03). Need for assistance was predicted by higher age, nationality other than Norwegian, lower KPS, and lower educational level (P ANDlt; 0.001). More than 50% of patients preferred computerized assessment to a paper and pencil version.\nConclusion. The high completion rate shows that symptom assessment by computers is feasible in patients with advanced cancer. However, reduced performance status reduces compliance and increases the need for assistance. Future work should aim at identifying the minimum set of valid screening questions and refine the software to optimize symptom assessment and reduce respondent burden in frail patients. J Pain Symptom Manage 2012;44:639-654. (c) 2012 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.\n\nHeitzer, Ellen\n\n\n"
},
{
"text": "\n131534\nTowards the introduction of the 'Immunoscore' in the classification of malignant tumours.\n\nGalon, J\n\nMlecnik, B\n\nBindea, G\n\nAngell, HK\n\nBerger, A\n\nLagorce, C\n\nLugli, A\n\nZlobec, I\n\nHartmann, A\n\nBifulco, C\n\nNagtegaal, ID\n\nPalmqvist, R\n\nMasucci, GV\n\nBotti, G\n\nTatangelo, F\n\nDelrio, P\n\nMaio, M\n\nLaghi, L\n\nGrizzi, F\n\nAsslaber, M\n\nD'Arrigo, C\n\nVidal-Vanaclocha, F\n\nZavadova, E\n\nChouchane, L\n\nOhashi, PS\n\nHafezi-Bakhtiari, S\n\nWouters, BG\n\nRoehrl, M\n\nNguyen, L\n\nKawakami, Y\n\nHazama, S\n\nOkuno, K\n\nOgino, S\n\nGibbs, P\n\nWaring, P\n\nSato, N\n\nTorigoe, T\n\nItoh, K\n\nPatel, PS\n\nShukla, SN\n\nWang, Y\n\nKopetz, S\n\nSinicrope, FA\n\nScripcariu, V\n\nAscierto, PA\n\nMarincola, FM\n\nFox, BA\n\nPagès, F\n\nBeiträge in Fachzeitschriften\nISI:000328220600012\n24122236.0\n10.1002/path.4287\nPMC4255306\nThe American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM staging system provides the most reliable guidelines for the routine prognostication and treatment of colorectal carcinoma. This traditional tumour staging summarizes data on tumour burden (T), the presence of cancer cells in draining and regional lymph nodes (N) and evidence for distant metastases (M). However, it is now recognized that the clinical outcome can vary significantly among patients within the same stage. The current classification provides limited prognostic information and does not predict response to therapy. Multiple ways to classify cancer and to distinguish different subtypes of colorectal cancer have been proposed, including morphology, cell origin, molecular pathways, mutation status and gene expression-based stratification. These parameters rely on tumour-cell characteristics. Extensive literature has investigated the host immune response against cancer and demonstrated the prognostic impact of the in situ immune cell infiltrate in tumours. A methodology named 'Immunoscore' has been defined to quantify the in situ immune infiltrate. In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC/UICC TNM classification. An international consortium has been initiated to validate and promote the Immunoscore in routine clinical settings. The results of this international consortium may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune).\n\nAsslaber, Martin\n\n\n"
},
{
"text": "\n138530\nTranscriptional regulatory program in wild-type and retinoblastoma gene-deficient mouse embryonic fibroblasts during adipocyte differentiation.\n\nHakim-Weber, R\n\nKrogsdam, AM\n\nJørgensen, C\n\nFischer, M\n\nProkesch, A\n\nBogner-Strauss, JG\n\nBornstein, SR\n\nHansen, JB\n\nMadsen, L\n\nKristiansen, K\n\nTrajanoski, Z\n\nHackl, H\n\nBeiträge in Fachzeitschriften\nNone\n21615920.0\n10.1186/1756-0500-4-157\nPMC3127957\nAlthough many molecular regulators of adipogenesis have been identified a comprehensive catalogue of components is still missing. Recent studies showed that the retinoblastoma protein (pRb) was expressed in the cell cycle and late cellular differentiation phase during adipogenesis. To investigate this dual role of pRb in the early and late stages of adipogenesis we used microarrays to perform a comprehensive systems-level analysis of the common transcriptional program of the classic 3T3-L1 preadipocyte cell line, wild-type mouse embryonic fibroblasts (MEFs), and retinoblastoma gene-deficient MEFs (Rb-/- MEFs).\n Comparative analysis of the expression profiles of 3T3-L1 cells and wild-type MEFs revealed genes involved specifically in early regulation of the adipocyte differentiation as well as secreted factors and signaling molecules regulating the later phase of differentiation. In an attempt to identify transcription factors regulating adipogenesis, bioinformatics analysis of the promoters of coordinately and highly expressed genes was performed. We were able to identify a number of high-confidence target genes for follow-up experimental studies. Additionally, combination of experimental data and computational analyses pinpointed a feedback-loop between Pparg and Foxo1.To analyze the effects of the retinoblastoma protein at the transcriptional level we chose a perturbated system (Rb-/- MEFs) for comparison to the transcriptional program of wild-type MEFs. Gene ontology analysis of 64 deregulated genes showed that the Rb-/- MEF model exhibits a brown(-like) adipocyte phenotype. Additionally, the analysis results indicate a different or additional role for pRb family member involvement in the lineage commitment.\n In this study a number of commonly modulated genes during adipogenesis in 3T3-L1 cells and MEFs, potential transcriptional regulation mechanisms, and differentially regulated targets during adipocyte differentiation of Rb-/- MEFs could be identified. These data and the analysis provide a starting point for further experimental studies to identify target genes for pharmacological intervention and ultimately remodeling of white adipose tissue into brown adipose tissue.\n\nProkesch, Andreas\n\n\n"
},
{
"text": "\n147064\nCurrent evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica.\n\nDejaco, C\n\nSingh, YP\n\nPerel, P\n\nHutchings, A\n\nCamellino, D\n\nMackie, S\n\nMatteson, EL\n\nDasgupta, B\n\nBeiträge in Fachzeitschriften\nISI:000361043200007\n26359489.0\n10.1136/annrheumdis-2015-207578\nNone\nTo summarise evidence on therapeutic interventions and prognostic factors in polymyalgia rheumatica (PMR). A systematic literature review was conducted using Ovid Medline, Embase, PubMed, CINAHL, Web of Science and the Cochrane Library (1970 through April 2014). Quality of evidence (QoE) of identified studies was appraised by Grading of Recommendations Assessment, Development and Evaluation (GRADE) (interventions) and the Quality In Prognosis Studies (QUIPS) methodologies (prognostic factors). Out of 10 931 titles identified, 52 articles were finally selected. A single study indicated that an initial prednisone dose of 20 mg/day is associated with a lower short-term relapse rate than 10 mg/day but at the cost of a higher rate of adverse events. Another study suggested a comparable efficacy of intramuscular methylprednisolone and oral glucocorticoids (GCs) with lower cumulative GC doses and less weight gain in the former group. Moderate to high QoE (1-2 studies) indicated a benefit of methotrexate in remission rates and cumulative GC doses in early PMR. Anti-tumour necrosis factor α agents are ineffective for PMR treatment. Among prognostic factors, female sex, high erythrocyte sedimentation rate (ESR) and peripheral arthritis were associated in some studies with a higher relapse risk. Women and patients with high ESR also appeared to have a longer duration of treatment. Several studies of varying quality, however, failed to prove these associations. In PMR, evidence for initial GC doses and subsequent tapering regimens is limited. Intramuscular methylprednisolone and methotrexate may be effective GC sparing agents. Female sex, high ESR and peripheral arthritis at disease outset are potential risk factors for a worse prognosis.\n Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.\n\nDejaco, Christian\n\n\n"
},
{
"text": "\n160163\nQuality of life and objective outcome assessment in women with tape division after surgery for stress urinary incontinence.\n\nUlrich, D\n\nBjelic-Radisic, V\n\nHöllein, A\n\nTrutnovsky, G\n\nTamussino, K\n\nAigmüller, T\n\nBeiträge in Fachzeitschriften\nISI:000399174300064\n28346541.0\n10.1371/journal.pone.0174628\nPMC5367714\nMidurethral tapes may cause long-term complications such as voiding dysfunction, groin pain, de novo urgency or mesh erosion, which necessitate a reoperation. There is a paucity of data regarding health related quality of life in patients undergoing tape removal. The aim of the study was to evaluate quality of life (QoL) and objective outcome after midurethral tape division or excision.\n All patients who underwent a midurethral tape division for voiding difficulties, pain or therapy resistant de novo overactive bladder between 1999 and 2014 were invited for follow-up. A control group with a suburethral tape without division was established in a 1:2 ratio and matched for age, tape used and year of tape insertion. Patients completed the Kings´ Health Questionnaire (KHQ), Incontinence Outcome Questionnaire, Female Sexual Function Index Questionnaire and the Patient Global Impression of Improvement score.\n Tape division or excision was performed in 32 women. Overall, 15 (60%) of 25 women who were alive were available for clinical examination and completed the questionnaires. Tape division was performed for voiding dysfunction (n = 7), overactive bladder (n = 2), mesh extrusion (n = 3) and ongoing pain (n = 3). Median time to tape division/excision was 10 months. Three women in the tape division group had undergone reoperation for stress urinary incontinence (SUI). At a median follow-up of 11 years (IQR 9-13) subjective SUI rate was 53% (8/15 women) in the tape division group and 17% (5/30) in the control group (p = 0.016), with no significant differences in objective SUI rates between groups. With regard to quality of life, the study group had significantly worse scores in the SUI related domains role limitation, physical limitation, severity measures and social limitations (KHQ) compared to the control group.\n Women needing tape division or excision have lower SUI related QoL scores compared to controls mostly because of higher subjective SUI rates.\n\nAigmüller, Thomas\n\nBjelic-Radisic, Vesna\n\nGold ehem Ulrich, Daniela\n\nTamussino, Karl\n\nTrutnovsky, Gerda\n\n\n"
},
{
"text": "\n168618\nEffects of Vitamin D Supplementation on Renin and Aldosterone Concentrations in Patients with Advanced Heart Failure: The EVITA Trial.\n\nZittermann, A\n\nErnst, JB\n\nProkop, S\n\nFuchs, U\n\nDreier, J\n\nKuhn, J\n\nKnabbe, C\n\nBörgermann, J\n\nBerthold, HK\n\nPilz, S\n\nGouni-Berthold, I\n\nGummert, JF\n\nBeiträge in Fachzeitschriften\nISI:000438879100001\n30057603.0\n10.1155/2018/5015417\nPMC6051119\n1, 5-Dihydroxyvitamin D (1, 5([OH]2D) is considered to be a negative endogenous regulator of the renin-angiotensin-aldosterone system (RAAS), but the effect of vitamin D supplementation on the RAAS is inconclusive.\n In this prespecified secondary analysis of a randomized controlled trial, we assessed in 165 patients with heart failure (vitamin D group: n = 83; placebo group: n = 82) the effect of three years of vitamin D supplementation with 4000 IU daily on parameters of the RAAS (renin and aldosterone) and on circulating 1, 5(OH)2D, plasma phosphate, and fibroblast growth factor (FGF)-23. We assessed age- and baseline-adjusted between-group differences at study termination.\n Almost all patients were under treatment with beta-blockers, inhibitors of the RAAS, and diuretics. Initially, the frequency of concentrations above the laboratory-specific reference range (renin: >23.9 mIU/L; aldosterone: >232 ng/L) in the vitamin D and placebo group was 87.7% and 92.7%, respectively (renin), and 24.1% and 32.5%, respectively (aldosterone). Vitamin D increased adjusted 1, 5(OH)2D concentrations significantly (mean treatment effect and 95% CI: 18.3 pmol/L, .3 to 29.3 pmol/L; P < 0.001) but had no significant effects on phosphate (0.18 mmol/L, -0.00 to 0.35 mmol/L; P = 0.051), FGF-23 (685 RU/mL, -213 to 1585 RU/mL; P = 0.134), renin (312 mIU/L, -279 to 902 ng/L; P = 0.298), or aldosterone (-0.19 ng/L, -5.09 to 4.70 ng/L; P = 0.938). Vitamin D supplementation was, however, associated with an increase in renin concentrations in the subgroup with baseline 25-hydroxyvitamin D below 30 nmol/L (n = 67; 1365 mIU/, 343 to 2386 mIU/L; P = 0.010).\n In patients with advanced heart failure treated according to evidence-based guidelines, vitamin D supplementation did not significantly influence parameters of the RAAS in the entire study cohort but was associated with an increase in plasma renin concentrations in the subgroup with low baseline 25-hydroxyvitamin D concentrations.\n\nPilz, Stefan\n\n\n"
},
{
"text": "\n182609\nTherapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.\n\nKuendgen, A\n\nNomdedeu, M\n\nTuechler, H\n\nGarcia-Manero, G\n\nKomrokji, RS\n\nSekeres, MA\n\nDella Porta, MG\n\nCazzola, M\n\nDeZern, AE\n\nRoboz, GJ\n\nSteensma, DP\n\nVan de Loosdrecht, AA\n\nSchlenk, RF\n\nGrau, J\n\nCalvo, X\n\nBlum, S\n\nPereira, A\n\nValent, P\n\nCosta, D\n\nGiagounidis, A\n\nXicoy, B\n\nDöhner, H\n\nPlatzbecker, U\n\nPedro, C\n\nLübbert, M\n\nOiartzabal, I\n\nDíez-Campelo, M\n\nCedena, MT\n\nMachherndl-Spandl, S\n\nLópez-Pavía, M\n\nBaldus, CD\n\nMartinez-de-Sola, M\n\nStauder, R\n\nMerchan, B\n\nList, A\n\nGanster, C\n\nSchroeder, T\n\nVoso, MT\n\nPfeilstöcker, M\n\nSill, H\n\nHildebrandt, B\n\nEsteve, J\n\nNomdedeu, B\n\nCobo, F\n\nHaas, R\n\nSole, F\n\nGerming, U\n\nGreenberg, PL\n\nHaase, D\n\nSanz, G\n\nBeiträge in Fachzeitschriften\nISI:000544188800001\n32595214.0\n10.1038/s41375-020-0917-7\nPMC7932916\nIn the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. Analyzing data of 2087 t-MDS patients from different international MDS groups to evaluate classification and prognostication tools we found that applying the WHO classification for p-MDS successfully predicts time to transformation and survival (both p < 0.001). The results regarding carefully reviewed cytogenetic data, classifications, and prognostic scores confirmed that t-MDS are similarly heterogeneous as p-MDS and therefore deserve the same careful differentiation regarding risk. As reference, these results were compared with 4593 primary MDS (p-MDS) patients represented in the International Working Group for Prognosis in MDS database (IWG-PM). Although a less favorable clinical outcome occurred in each t-MDS subset compared with p-MDS subgroups, FAB and WHO-classification, IPSS-R, and WPSS-R separated t-MDS patients into differing risk groups effectively, indicating that all established risk factors for p-MDS maintained relevance in t-MDS, with cytogenetic features having enhanced predictive power. These data strongly argue to classify t-MDS as a separate entity distinct from other WHO-classified t-myeloid neoplasms, which would enhance treatment decisions and facilitate the inclusion of t-MDS patients into clinical studies.\n\nSill, Heinz\n\n\n"
},
{
"text": "\n184052\n[Jury prize of the Austrian National Prize 2018 : 12 years European Foundation for Quality Management (EFQM) at the University Eye Clinic Graz].\n\nLangmann, G\n\nGliebe, W\n\nGranitz, E\n\nKohlhofer, A\n\nReinisch, S\n\nIvastinovic, D\n\nWedrich, A\n\nBeiträge in Fachzeitschriften\nISI:000582089100002\n33095296.0\n10.1007/s00347-020-01234-y\nNone\nThe European Foundation for Quality Management (EFQM) approach has been successfully implemented in healthcare but reports about EFQM awards at university clinics are lacking so far. Can a non-profit organization, such as a university eye department successfully compete with profit companies from industry for the National Prize of the Federal Ministry for Innovation and Business in Austria?\n Following successful committed to excellence (C2E) assessments in 2008 and 2010, a 70-page corporate report was compiled strictly according to the EFQM logic (latest version 2013), consisting of basic concepts, criteria matrix and results/approach/deployment/assessment and refinement (RADAR) logic, which formed the basis for an 1‑day assessment in 2018. Special emphasis was laid on the development and presentation of the strategy by means of the X‑matrix (according to Hoshin-Kanri) between the University Eye Department and its shareholders, the Styrian Hospital Association (KAGes) owned by the Federal State of Styria and the Medical University financed by the Austrian State Federal Ministry.\n The total points score in the recognized for excellence (R4E) assessment 2018 was 500-550 points, which prompted the jury to award a jury prize of the Austrian National Prize (focus: participative leadership). Potential for improvement, which needs to be worked on in the near future was the alignment of core processes with the main performance indicators of the University Eye Department, which arises from its mission consisting of patient care, research, teaching, training and public relations activities. The development of the strategy with the shareholders has developed from a potential to a strength compared to the R4E assessment from 2017.\n Feedback from the assessor team after the site visit is the greatest added value for a university eye department and/or business enterprise. Improvement measures can be effectively derived following the RADAR logic and lead to a higher quality standard/score and improved performance.\n\nIvastinovic, Domagoj\n\nLangmann, Gerald\n\nWedrich, Andreas\n\n\n"
},
{
"text": "\n184459\nDevelopment and external validation of nomograms to predict sarcoma-specific death and disease progression after surgical resection of localized high-grade conventional primary central chondrosarcoma and dedifferentiated chondrosarcoma.\n\nTsuda, Y\n\nTsoi, K\n\nStevenson, JD\n\nLaitinen, M\n\nFerguson, PC\n\nWunder, JS\n\nGriffin, AM\n\nvan de Sande, MAJ\n\nvan Praag, V\n\nLeithner, A\n\nFujiwara, T\n\nYasunaga, H\n\nMatsui, H\n\nParry, MC\n\nJeys, LM\n\nBeiträge in Fachzeitschriften\nISI:000595479300022\n33249892.0\n10.1302/0301-620X.102B12.BJJ-2020-0810.R1\nNone\nOur aim was to develop and validate nomograms that would predict the cumulative incidence of sarcoma-specific death (CISSD) and disease progression (CIDP) in patients with localized high-grade primary central and dedifferentiated chondrosarcoma.\n The study population consisted of 391 patients from two international sarcoma centres (development cohort) who had undergone definitive surgery for a localized high-grade (histological grade II or III) conventional primary central chondrosarcoma or dedifferentiated chondrosarcoma. Disease progression captured the first event of either metastasis or local recurrence. An independent cohort of 221 patients from three additional hospitals was used for external validation. Two nomograms were internally and externally validated for discrimination (c-index) and calibration plot.\n In the development cohort, the CISSD at ten years was 32.9% (95% confidence interval (CI) 19.8% to 38.4%). Age at diagnosis, grade, and surgical margin were found to have significant effects on CISSD and CIDP in multivariate analyses. Maximum tumour diameter was also significantly associated with CISSD. In the development cohort, the c-indices for CISSD and CIDP at five years were 0.743 (95% CI 0.700 to 0.819) and 0.761 (95% CI 0.713 to 0.800), respectively. When applied to the validation cohort, the c-indices for CISSD and CIDP at five years were 0.839 (95% CI 0.763 to 0.916) and 0.749 (95% CI 0.672 to 0.825), respectively. The calibration plots for these two nomograms demonstrated good fit.\n Our nomograms performed well on internal and external validation and can be used to predict CISSD and CIDP after resection of localized high-grade conventional primary central and dedifferentiated chondrosarcomas. They provide a new tool with which clinicians can assess and advise individual patients about their prognosis. Cite this article: Bone Joint J 2020;102-B(12):1752-1759.\n\nLeithner, Andreas\n\n\n"
},
{
"text": "\n186810\nFunctional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT?\n\nSchmid-Bindert, G\n\nHenzler, T\n\nChu, TQ\n\nMeyer, M\n\nNance, JW\n\nSchoepf, UJ\n\nDinter, DJ\n\nApfaltrer, P\n\nKrissak, R\n\nManegold, C\n\nSchoenberg, SO\n\nFink, C\n\nBeiträge in Fachzeitschriften\nNone\n21822784.0\n10.1007/s00330-011-2230-3\nNone\nTo investigate the correlation between maximum standardized uptake value (SUV(max)) of (18)FDG PET-CT and iodine-related attenuation (IRA) of dual energy CT (DECT) of primary tumours and (18)FDG PET-CT positive thoracic lymph nodes (LN) in patients with lung cancer.\n 37 patients with lung cancer (27 NSCLC, 10 SCLC, 86 (18)FDG PET-CT positive thoracic LN) who underwent both (18)FDG PET-CT and DECT were analyzed. The mean study interval between (18)FDG PET-CT and DECT was ≤21 days in 17 patients. The mean and maximum IRA of DECT as well as of virtual unenhanced and virtual 120 kV images of DECT was analyzed and correlated to the SUV(max) of (18)FDG PET-CT in all tumours and (18)FDG PET-CT positive thoracic lymph nodes. Further subgroup analysis was performed for histological subtypes in all groups.\n A moderate correlation was found between SUV(max) and maximum IRA in all tumours (n = 37;r = 0.507;p = 0.025) whereas only weak or no correlation were found between SUV(max) and all other DECT measurements. A strong correlation was found in patients with study intervals ≤21 days (n = 17; r = 0.768;p = 0.017). Analysis of histological subtypes of lung cancer showed a strong correlation between SUV(max) and maximum IRA in the analysis of all patients with NSCLC (r = 0.785;p = 0.001) and in patients with NSCLC and study intervals ≤21 days (r = 0.876;p = 0.024). Thoracic LN showed moderate correlation between SUV(max) and maximum IRA in patients with study intervals ≤21 days (r = 0.654; p = 0.010) whereas a weak correlation was found between SUV(max) and maximum IRA in patients with study intervals >21 days (r = 0.299; p = 0.035).\n DECT could serve as a valuable functional imaging test for patients with NSCLC as the IRA of DECT correlates with SUV(max) of (18)FDG PET-CT.\n\nApfaltrer, Paul\n\n\n"
}
]
}